--- title: "Metagenomi Therapeutics (MGX) news: class action and IPO" url: "https://aibio.space/companies/metagenomi-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "MGX class action, IPO and offering news: Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery." --- MGX Metagenomi Therapeutics, Inc. NASDAQ · United States # Metagenomi Therapeutics (MGX) news MGX class action, IPO and offering news Legal · 2026-08-10 ## [Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery](https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/) Vreeland v. Metagenomi names the company, unnamed officers and directors under Section 11. The court partly denied dismissal on March 24, 2026; the S-1 shows who signed. ## Latest Metagenomi Therapeutics news 1. 2025-03-17 Financings [Metagenomi files $250,000,000 shelf and $75,000,000 at-the-market program](https://aibio.space/news/metagenomi-files-250-000-000-shelf-75-000-000-market-program/) Metagenomi filed a $250,000,000 shelf and signed a $75,000,000 at-the-market sales agreement with Jefferies LLC, which can earn up to 3.0% commission. The filing does not state the company's cash balance, and sales can start only after the registration statement is declared effective. ## Metagenomi Therapeutics at a glance - **Ticker**: MGX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $120.7 million ### Related companies - [Seaport Therapeutics](https://aibio.space/companies/seaport-therapeutics/) NASDAQ: SPTX - [Atea Pharmaceuticals](https://aibio.space/companies/atea-pharmaceuticals/) NASDAQ: AVIR - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO - [Trevena](https://aibio.space/companies/trevena/) OTC: TRVN - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) NASDAQ: SGMT - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI - [REGENXBIO](https://aibio.space/companies/regenxbio/) NASDAQ: RGNX - [Eton Pharmaceuticals](https://aibio.space/companies/eton-pharmaceuticals/) NASDAQ: ETON ### Also on NASDAQ - [Sagimet Biosciences](https://aibio.space/companies/sagimet-biosciences/) SGMT - [IRIDEX CORP](https://aibio.space/companies/iridex/) IRIX - [Tiziana Life Sciences](https://aibio.space/companies/tiziana-life-sciences/) TLSA - [Artiva Biotherapeutics](https://aibio.space/companies/artiva-biotherapeutics/) ARTV - [IDEXX LABORATORIES INC /DE](https://aibio.space/companies/idexx-laboratories-de/) IDXX - [Cullinan Therapeutics](https://aibio.space/companies/cullinan-therapeutics/) CGEM ## Metagenomi Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$25.2 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | [$52.3 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | | Research and development | [$94.4 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | [$109.2 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | | Net income (loss) | [-$87.9 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | [-$78.1 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | | Cash from operations | [-$88.9 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | [-$109.1 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | | Cash and equivalents | [$41.7 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526342400/) | [$27.4 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | | Short-term investments | [$119.1 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526342400/) | [$220.9 million](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $39.0 million, plus short-term investments of $81.6 million, $120.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Metagenomi Therapeutics Is there a class action against Metagenomi Therapeutics? Our latest story on this, dated Aug 10, 2026: "Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/). When did Metagenomi Therapeutics go public? Our latest story on this, dated Aug 10, 2026: "Metagenomi's IPO class action over Moderna collaboration disclosures moves into discovery". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/metagenomis-ipo-class-action-moderna-collaboration-disclosures-moves/). Has Metagenomi Therapeutics raised money recently? Our latest story on this, dated Mar 17, 2025: "Metagenomi files $250,000,000 shelf and $75,000,000 at-the-market program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/metagenomi-files-250-000-000-shelf-75-000-000-market-program/). What is the ticker symbol of Metagenomi Therapeutics? Metagenomi Therapeutics, Inc. trades under the ticker MGX on NASDAQ. Where is Metagenomi Therapeutics listed? Metagenomi Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Metagenomi Therapeutics? The SEC Central Index Key (CIK) for Metagenomi Therapeutics, Inc. is 1785279. Its filings are on SEC EDGAR. How many shares does Metagenomi Therapeutics have outstanding? 37,777,105 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-10. Which country or territory is Metagenomi Therapeutics listed under? Our directory records Metagenomi Therapeutics, Inc. under United States. What does Metagenomi Therapeutics do? Our directory classifies Metagenomi Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Metagenomi Therapeutics? The ISIN recorded for Metagenomi Therapeutics, Inc. is US59102M1045. Does aibio.space cover Metagenomi Therapeutics? aibio.space lists Metagenomi Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. What was Metagenomi Therapeutics's revenue last year? $25.2 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Metagenomi Therapeutics profitable? Metagenomi Therapeutics, Inc. reported a net loss of $87.9 million for the fiscal year ended Dec 31, 2025, and used $88.9 million of cash in operations, per its annual report to the SEC. How much does Metagenomi Therapeutics spend on research and development? $94.4 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Metagenomi Therapeutics have? $120.7 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Metagenomi Therapeutics Members talk about Metagenomi Therapeutics (MGX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Metagenomi Therapeutics, newest first. Each line links the filing it comes from. 1. 2025-10-01 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1785279/000119312525226878/mgx-20250929.htm) 2. 2025-03-17 Financings Reported a financing. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1785279/000095017025040421/mgx-20250317.htm) 3. 2024-11-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1785279/000095017024126273/mgx-20240930.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:MGX on TradingView](https://www.tradingview.com/symbols/NASDAQ-MGX/). ## SEC filings and registration - **SEC name**: Metagenomi Therapeutics, Inc. - **CIK**: 1785279 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: MGX (Nasdaq) - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 5959 HORTON STREET, EMERYVILLE, CA, 94608 - **Phone**: (510) 871-4880 - **Shares outstanding**: 37,777,105 as of 2026-08-06 (10-Q filed 2026-08-10) - **Former names**: Metagenomi, Inc.; Metagenomi Technologies, LLC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1785279/000119312526397037/mgx-20260921.htm) filed 2026-09-22 - [10-Q](https://www.sec.gov/Archives/edgar/data/1785279/000119312526342400/mgx-20260630.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1785279/000119312526342388/mgx-20260810.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1785279/000119312526264392/mgx-20260609.htm) filed 2026-06-10 - [10-Q](https://www.sec.gov/Archives/edgar/data/1785279/000119312526216774/mgx-20260331.htm) filed 2026-05-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1785279/000119312526216763/mgx-20260511.htm) filed 2026-05-11 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1785279/000119312526182325/mgx-20260421.htm) filed 2026-04-27 - [10-K](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093976/mgx-20251231.htm) filed 2026-03-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001785279), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Metagenomi Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker MGX, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Metagenomi Therapeutics, Inc. - **Ticker**: MGX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US59102M1045 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-MGX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/metagenomi-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Metagenomi Therapeutics (MGX) news: class action and IPO", 2026-10-31, https://aibio.space/companies/metagenomi-therapeutics/